JP2021501566A - Cd138に対する抗体分子およびその使用 - Google Patents

Cd138に対する抗体分子およびその使用 Download PDF

Info

Publication number
JP2021501566A
JP2021501566A JP2020518692A JP2020518692A JP2021501566A JP 2021501566 A JP2021501566 A JP 2021501566A JP 2020518692 A JP2020518692 A JP 2020518692A JP 2020518692 A JP2020518692 A JP 2020518692A JP 2021501566 A JP2021501566 A JP 2021501566A
Authority
JP
Japan
Prior art keywords
antibody molecule
amino acid
antibody
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020518692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501566A5 (cg-RX-API-DMAC7.html
Inventor
バラット チャガンティ,
バラット チャガンティ,
ブーパシー ラマクリシュナン,
ブーパシー ラマクリシュナン,
ヘディ アダリ−ホール,
ヘディ アダリ−ホール,
カルシク ビスワナサン,
カルシク ビスワナサン,
ジェイムズ アール. マイエット,
ジェイムズ アール. マイエット,
ザッカリー シュリバー,
ザッカリー シュリバー,
Original Assignee
ビステラ, インコーポレイテッド
ビステラ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビステラ, インコーポレイテッド, ビステラ, インコーポレイテッド filed Critical ビステラ, インコーポレイテッド
Publication of JP2021501566A publication Critical patent/JP2021501566A/ja
Publication of JP2021501566A5 publication Critical patent/JP2021501566A5/ja
Priority to JP2023186940A priority Critical patent/JP2024001294A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020518692A 2017-10-02 2018-10-02 Cd138に対する抗体分子およびその使用 Pending JP2021501566A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023186940A JP2024001294A (ja) 2017-10-02 2023-10-31 Cd138に対する抗体分子およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762566936P 2017-10-02 2017-10-02
US62/566,936 2017-10-02
US201862725880P 2018-08-31 2018-08-31
US62/725,880 2018-08-31
PCT/US2018/053989 WO2019070726A1 (en) 2017-10-02 2018-10-02 CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023186940A Division JP2024001294A (ja) 2017-10-02 2023-10-31 Cd138に対する抗体分子およびその使用

Publications (2)

Publication Number Publication Date
JP2021501566A true JP2021501566A (ja) 2021-01-21
JP2021501566A5 JP2021501566A5 (cg-RX-API-DMAC7.html) 2021-11-11

Family

ID=63966111

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020518692A Pending JP2021501566A (ja) 2017-10-02 2018-10-02 Cd138に対する抗体分子およびその使用
JP2023186940A Pending JP2024001294A (ja) 2017-10-02 2023-10-31 Cd138に対する抗体分子およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023186940A Pending JP2024001294A (ja) 2017-10-02 2023-10-31 Cd138に対する抗体分子およびその使用

Country Status (14)

Country Link
US (2) US11945868B2 (cg-RX-API-DMAC7.html)
EP (1) EP3692069A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021501566A (cg-RX-API-DMAC7.html)
KR (1) KR20200058540A (cg-RX-API-DMAC7.html)
CN (2) CN111183157A (cg-RX-API-DMAC7.html)
AU (1) AU2018345637A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020005419A2 (cg-RX-API-DMAC7.html)
CA (1) CA3074032A1 (cg-RX-API-DMAC7.html)
IL (2) IL320863A (cg-RX-API-DMAC7.html)
MX (1) MX2020003783A (cg-RX-API-DMAC7.html)
MY (1) MY205689A (cg-RX-API-DMAC7.html)
PH (1) PH12020550141A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202002248TA (cg-RX-API-DMAC7.html)
WO (1) WO2019070726A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110691793A (zh) * 2017-04-26 2020-01-14 田边三菱制药株式会社 黏结蛋白聚糖-1(cd138)结合剂及其用
IL320863A (en) 2017-10-02 2025-07-01 Visterra Inc Antibodies to CD138 and their uses
BR112021025421A2 (pt) * 2019-06-17 2022-02-01 Visterra Inc Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
WO2021092044A1 (en) * 2019-11-05 2021-05-14 Bristol-Myers Squibb Company M-protein assays and uses thereof
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
WO2023275872A1 (en) * 2021-06-29 2023-01-05 Tel Hashomer Medical Research Infrastructure And Services Ltd. Diagnosis and treatment of pancreatic cancer
CN113514645A (zh) * 2021-07-13 2021-10-19 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) CD138抗体联合Mum1抗体在检测浆细胞中的应用
US20230348614A1 (en) 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
CN115120725B (zh) * 2022-05-30 2023-11-07 南方医科大学 Sdc1作为骨质破坏疾病药物治疗靶点的应用
CN115960231B (zh) * 2022-09-28 2026-05-22 合肥天港免疫药物有限公司 抗cd138的抗体及其应用
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
CN121021703A (zh) * 2025-08-26 2025-11-28 苏州系统医学研究所 Glyr1特异性抗体、其制备方法及在肿瘤防治中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080829A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Agents targeting cd138 and uses thereof
US20090169570A1 (en) * 2007-12-26 2009-07-02 Benjamin Daelken Methods and agents for improving targeting of cd138 expressing tumor cells

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP1356093A2 (en) 2000-06-21 2003-10-29 Hitachi Chemical Co., Ltd. Gene markers for lung cancer
AU2004224925C1 (en) 2004-08-30 2011-07-21 Biotest Ag Immunoconjugates targeting syndecan-1 expressing cells and use thereof
EP2551282A3 (en) * 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
US20070054332A1 (en) * 2005-08-10 2007-03-08 Alan Rapraeger Syndecan 1 ectodomain inhibits cancer
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US9011864B2 (en) 2007-12-26 2015-04-21 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
PL2242772T3 (pl) 2007-12-26 2015-05-29 Biotest Ag Immunokonjugaty nakierowane na CD138 i ich zastosowanie
CA2761120A1 (en) 2009-05-06 2010-11-11 Biotest Ag Uses of immunoconjugates targeting cd138
US9249467B2 (en) 2011-09-16 2016-02-02 Steven Goodison Bladder cancer detection composition, kit and associated methods
US10577543B2 (en) 2011-10-27 2020-03-03 Raymond Roger Wallage Efficient oil shale recovery method
US10117932B2 (en) 2011-12-08 2018-11-06 Biotest Ag Uses of immunoconjugates targeting CD138
CA2866612C (en) 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
GB201216002D0 (en) 2012-09-07 2012-10-24 Deutsches Rheuma Forschungszentrum Berlin Drfz Compositions adn methods
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
CN103103197A (zh) 2013-01-30 2013-05-15 百奇生物科技(苏州)有限公司 抗cd138单克隆抗体可变区序列及其制备方法和应用
RU2611685C2 (ru) 2015-07-20 2017-02-28 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
IL320863A (en) 2017-10-02 2025-07-01 Visterra Inc Antibodies to CD138 and their uses
CN119405833A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
CA3141914A1 (en) 2019-06-07 2020-12-10 Adimab, Llc Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use
BR112021025421A2 (pt) 2019-06-17 2022-02-01 Visterra Inc Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
US12590171B2 (en) 2019-09-27 2026-03-31 Nanjing GenScript Biotech Co., Ltd. Anti-VHH domain antibodies and use thereof
US20230348614A1 (en) 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080829A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Agents targeting cd138 and uses thereof
US20090169570A1 (en) * 2007-12-26 2009-07-02 Benjamin Daelken Methods and agents for improving targeting of cd138 expressing tumor cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BR. J. HAEMATOL., vol. Vol. 104, Issue 1, JPN6022042066, 1999, pages 152 - 162, ISSN: 0004889041 *
EUR. J. CANCER, vol. 49, JPN6022042064, 2013, pages 2022 - 2033, ISSN: 0004889039 *
VET. COMP. ONCOL., vol. Vol. 15, Issue 3, JPN6022042065, 2017, pages 932 - 951, ISSN: 0004889040 *

Also Published As

Publication number Publication date
IL273572B1 (en) 2025-06-01
EP3692069A1 (en) 2020-08-12
WO2019070726A1 (en) 2019-04-11
BR112020005419A2 (pt) 2020-09-29
JP2024001294A (ja) 2024-01-09
PH12020550141A1 (en) 2020-12-07
MY205689A (en) 2024-11-06
SG11202002248TA (en) 2020-04-29
CN111183157A (zh) 2020-05-19
IL273572A (en) 2020-05-31
AU2018345637A1 (en) 2020-03-05
IL320863A (en) 2025-07-01
KR20200058540A (ko) 2020-05-27
IL273572B2 (en) 2025-10-01
US20190100588A1 (en) 2019-04-04
US20240301065A1 (en) 2024-09-12
MX2020003783A (es) 2021-01-08
US11945868B2 (en) 2024-04-02
CA3074032A1 (en) 2019-04-11
CN119192374A (zh) 2024-12-27

Similar Documents

Publication Publication Date Title
US20240301065A1 (en) Antibody molecules to cd138 and uses thereof
CN113248618B (zh) 抗pd-l1/抗lag3双特异性抗体及其用途
JP6826055B2 (ja) 抗pdl1抗体、活性化可能抗pdl1抗体、およびその使用方法
JP7716342B2 (ja) Cd138に対するヒト化抗体分子およびその使用
KR20190133160A (ko) 항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자
JP2019528083A (ja) 抗pd−l1抗体
US11560425B2 (en) Use of anti-FAM19A5 antibodies for treating cancers
JP2026001069A (ja) 癌免疫療法のための併用療法での多重特異性抗体
JP2022512905A (ja) 新規アンタゴニスト抗tnfr2抗体分子
CA3186256A1 (en) Anti-lilrb1 antibody and uses thereof
US20230348614A1 (en) Engineered antibody molecules to cd138 and uses thereof
HK40115904A (en) Antibody molecules to cd138 and uses thereof
EA048240B1 (ru) Молекулы антител против cd138 и их применение
HK40027058A (en) Antibody molecules to cd138 and uses thereof
HK40068842A (en) Humanized antibody molecules to cd138 and uses thereof
HK40057471B (en) Anti-pd-l1/anti-lag3 bispecific antibody and use thereof
HK40057471A (en) Anti-pd-l1/anti-lag3 bispecific antibody and use thereof
HK40019833A (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
HK40019833B (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
EA039736B1 (ru) Анти-pdl1-антитела, активируемые анти-pdl1-антитела и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230405

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231031

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231127

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240119